search
Back to results

Sunweavers: Supporting Native American Women's Vitamin D Research

Primary Purpose

Vitamin D Deficiency, Cardiovascular Diseases

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Vitamin D Deficiency

Eligibility Criteria

55 Years - 75 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Ambulatory, community dwelling AI woman
  • Postmenopausal up to age 75 years; for women below age 55, postmenopausal status must be confirmed by documentation of serum FSH>30 IU/L and estradiol < 20 pg/ml unless a bilateral oophorectomy is documented.

Exclusion Criteria:

  • Serum 25(OH)D < 10 or > 60 ng/ml.
  • Known CVD (history of MI, coronary artery bypass graft surgery, percutaneous coronary intervention, stroke, transient ischemic attack, peripheral arterial disease with claudication).
  • Uncontrolled thyroid disease (thyroid stimulating hormone level outside of normal range).
  • Change in dose of lipid lowering medications within the preceding six weeks.
  • Mastectomy of the right breast
  • Non-English speaking, illiterate, impaired decision making.

Sites / Locations

  • Stockbridge-Munsee Nation
  • Bad River Nation
  • University of Wisconsin Osteoporosis Clinical Research Program

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

2500 IU Vitamin D3

400 IU Vitamin D3

Arm Description

Outcomes

Primary Outcome Measures

Change in markers of endothelial function
This will be determined by evaluating CRP and lipid panel
Change in arterial stiffness with vitamin D3 supplementation
Change in arterial stiffness will be evaluated with radial tonometry.

Secondary Outcome Measures

Plasma concentration of pro-inflammatory cytokines
This will be evaluated by assessing TNF alpha, IL6, VCAM and ICAM

Full Information

First Posted
November 29, 2011
Last Updated
November 19, 2014
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT01490333
Brief Title
Sunweavers: Supporting Native American Women's Vitamin D Research
Official Title
Sunweavers: Supporting Native American Women's Vitamin D Research
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
July 2011 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cardiovascular disease (CVD) and diabetes occur commonly among Native Americans (NA), and are leading causes of death among northern US NAs. Moreover, low vitamin D status occurs commonly in this same population. An increasing amount of evidence indicates a correlation between low vitamin D status and CVD and diabetes by contributing to a heightened pro-inflammatory environment within the endothelial lining of blood vessels leading to atherosclerotic disease, and an impaired sensitivity to insulin leading to diabetes. Our fundamental hypothesis is that low vitamin D status is a risk factor for CVD by causing a proinflammatory milieu, thereby leading to endothelial dysfunction. Additionally, the investigators hypothesize that vitamin D supplementation will reduce inflammation, thereby restoring endothelial function and ultimately reducing CVD risk.
Detailed Description
Low vitamin D status is endemic due to 21st century lifestyle, which limits sun exposure, and inadequate dietary intake. An increasing body of data relates low vitamin D status to increased risk for non-musculoskeletal morbidities including, most notably, cardiovascular disease (CVD) and type II diabetes mellitus (T2DM). CVD, for which T2DM is a major risk factor, causes over one-third of all deaths in the US. Moreover, American Indians (AI) and Alaskan Natives (AN) are 20% more likely to develop CVD and 2.2 times more likely to develop DM than non-Hispanic whites. In fact, AI of the Great Lakes Region (Bemidji Area) have the third highest DM rate in the nation, an age-adjusted DM mortality rate almost three-fold higher than the all-race mortality, and the highest rates of CVD among AI nationally. In this population, where CVD and DM are two of the top four causes of death, our preliminary work finds low vitamin D status commonplace. As low vitamin D status, CVD and T2DM are epidemic among AI, the investigators hypothesize that low vitamin D is causally related to CVD and T2DM by establishing a pro-inflammatory milieu, which in turn predisposes to CVD and T2DM. As such, vitamin D supplementation should reduce markers of inflammation and thereby ultimately reduce risk for CVD and T2DM. This work will explore this possibility by evaluating the effect of vitamin D status on endothelial function (measured by arterial reactivity), plasma biomarkers of inflammation and glucose homeostasis in 100 postmenopausal AI women. Subjects will receive vitamin D3, either 400 or 2,500 IU, daily for six months. The investigators will define the effects of vitamin D status, and subsequent response to supplementation, on endothelial function, arterial stiffness (flow-mediated vasodilation (FMD) of the brachial artery, and carotid to femoral pulse wave velocity (PWV)), plasma markers of inflammation and glucose homeostasis. All study participants will have fasting laboratory and noninvasive vascular ultrasound studies performed at baseline and following three and six months of study. Plasma concentration of pro-inflammatory cytokines will be measured as secondary outcome variables. Fasting blood glucose, insulin and the adipocytokines leptin and adiponectin, will be measured as exploratory outcomes for potential future studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency, Cardiovascular Diseases

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
99 (Actual)

8. Arms, Groups, and Interventions

Arm Title
2500 IU Vitamin D3
Arm Type
Experimental
Arm Title
400 IU Vitamin D3
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3
Intervention Description
The vitamin D3 will be taken daily.
Primary Outcome Measure Information:
Title
Change in markers of endothelial function
Description
This will be determined by evaluating CRP and lipid panel
Time Frame
Baseline visit, 3 month visit and 6 month visit.
Title
Change in arterial stiffness with vitamin D3 supplementation
Description
Change in arterial stiffness will be evaluated with radial tonometry.
Time Frame
one year
Secondary Outcome Measure Information:
Title
Plasma concentration of pro-inflammatory cytokines
Description
This will be evaluated by assessing TNF alpha, IL6, VCAM and ICAM
Time Frame
Baseline visit, 3 month visit, and 6 month visit.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Ambulatory, community dwelling AI woman Postmenopausal up to age 75 years; for women below age 55, postmenopausal status must be confirmed by documentation of serum FSH>30 IU/L and estradiol < 20 pg/ml unless a bilateral oophorectomy is documented. Exclusion Criteria: Serum 25(OH)D < 10 or > 60 ng/ml. Known CVD (history of MI, coronary artery bypass graft surgery, percutaneous coronary intervention, stroke, transient ischemic attack, peripheral arterial disease with claudication). Uncontrolled thyroid disease (thyroid stimulating hormone level outside of normal range). Change in dose of lipid lowering medications within the preceding six weeks. Mastectomy of the right breast Non-English speaking, illiterate, impaired decision making.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neil Binkley, M.D.
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stockbridge-Munsee Nation
City
Bowler
State/Province
Wisconsin
ZIP/Postal Code
54416
Country
United States
Facility Name
Bad River Nation
City
Lac du Flambeau
State/Province
Wisconsin
ZIP/Postal Code
54538
Country
United States
Facility Name
University of Wisconsin Osteoporosis Clinical Research Program
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25955191
Citation
Gepner AD, Haller IV, Krueger DC, Korcarz CE, Binkley N, Stein JH. A randomized controlled trial of the effects of vitamin D supplementation on arterial stiffness and aortic blood pressure in Native American women. Atherosclerosis. 2015 Jun;240(2):526-8. doi: 10.1016/j.atherosclerosis.2015.04.795. Epub 2015 Apr 25.
Results Reference
derived

Learn more about this trial

Sunweavers: Supporting Native American Women's Vitamin D Research

We'll reach out to this number within 24 hrs